Jul 17, 2024 7:00 am EDT MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
Jun 21, 2024 7:00 am EDT MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Jun 20, 2024 7:00 am EDT MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
May 9, 2024 8:00 am EDT New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
May 4, 2024 8:00 am EDT MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
May 2, 2024 7:00 am EDT MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update